Soluble CD-4 and CD-8 as markers of immunological activation in renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 15, Issue 1, 2000, Pages 71-77

  Grunewald, R Willi ^a   Fiedler, G Martin ^b   Stock, Birgit ^b   Grunewald, Julia M ^b   Müller, Gerhard A ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NONE

Author keywords

CMV infection; Cyclosporin A nephrotoxicity; Immune monitoring; Renal allograft rejection; Soluble CD 4; Soluble CD 8

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033971116     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.1.71     Document Type: Article

References (48)

1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331: 365-376
2. Colvin RB. The renal allograft biopsy. Kidney Int 1996; 50: 1069-1082
3. Gay D, Maddon P, Sekaly R et al. Functional interaction between human CD4 and the major histocompatibility complex HLA-DR-antigen. Nature 1987; 328: 626-629
4. Gilliland LK, Teh SH, Uckun FM et al. CD4 and CD8 are positive regulators of T-cell receptor signal transduction in early T cell differentiation. J Immunol 1991; 146: 1759-1765
5. Moebius U, Kober G, Griscelli AL, Hercend T, Meuser SC. Expression of different CD8 isoforms on distinct human lymphocyte subpopulations. Eur J Immunol 1991; 21: 1793-1800
6. Geppert TD, Lipsky PE. Association of various T-cell-surface molecules with cyto-skeleton. J Immunol 1991; 146: 3298-3305
7. Fleischer B, Schrezenmeier H. Do CD4 or CDS molecules provide a regulatory signal in T-cell activation? Immunol Today 1988; 9: 132-134
8. Kay JE. Mechanism of T lymphocyte activation. Immunol Lett 1991; 29: 51-54
9. Smith KA. Interleukin-2 inception, impact, and implications. Science 1988; 240: 1169-1176
10. Furukawa S, Matsubara T, Tsuji K, Motohashi T, Okumura K, Yabuta K. Serum soluble CD-4 and CD-8 levels in Kawasaki disease. Clin Exp Immunol 1991; 86: 134-139
11. Yoneyama A, Nakahara K, Higashihara M, Kurokawa K. Increased levels of soluble CD8 and CD4 in patients with infectious mononucleosis. Br J Haematol 1995; 89: 47-54
12. Onji M, Doi Y, Miyaoka H, Masumoto T, Horiike N, Ohta Y. Serum levels of soluble CD4 and CD8 in patients with chronic viral hepatitis. Hepatogastroenterology 1994; 41: 377-379
13. Reddy MM, Vodian M, Grieco MH. Elevated levels of CD4 antigen in sera of human immunodeficiency virus-infected populations. J Clin Microbiol 1990; 28: 1744-1746
14. Nishanian P, Hofmann B, Wang Y, Jackson AL, Detels R, Fahey JL. Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-disease. AIDS 1991; 5: 805-812
15. + cells in HIV-1-infected and high-risk individuals. Clin Immunol Immunopathol 1994; 73: 252-260
16. Pui CH, Ip SH, Dodge RK et al. Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients. Blood 1988; 72: 1015-1021
17. Pui CH, Ip SH, Thompson E et al. Increased serum CD8 antigen level in child-hood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood 1989; 73: 209-213
18. Srivastava MD, Srivastava A, Srivastava BI. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies. Leuk Lymphoma 1994; 12: 241-251
19. Symons JA, Wood NC, Di-Giovine FS, Duff GW. Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol 1990; 80: 354-359
20. Symons JA, McCulloch JF, Wood NC, Duff GW. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol 1991; 60: 72-82
21. Lipnick RN, Sfikakis PP, Klipple GL, Tsokos GC. Elevated soluble CD8 antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis. Clin Immunol Immunopathol 1993; 68: 64-67
22. Salvarani C, Boiardi L, Macchioni P et al. Serum soluble CD4 and CD8 levels in polymyalgia rheumatica. J Rheumatol 1994; 21: 1865-1869
23. Swada S, Hashimoto H, Iijima S et al. Immunologic significance of increased soluble CD8/CD4 molecules in patients with active lupus erythematosus. J Clin Lab Anal 1993; 7: 141-146
24. Di Cesare E, Previti M, Ingemi MC, Bagnato GF, Cucinotta D. High serum levels of soluble CD8 in insulin-dependent diabetes. Clin Exp Immunol 1994; 95: 283-286
25. Maimone D, Reder AT. Soluble CD8 levels in the CSF and serum of patients with multiple sclerosis. Neurology 1991; 41: 851-854
26. Apperl A, Stockenhuber F, Steininger R et al. Soluble interleukin-2 receptor (sIL-2R) - a novel parameter of renal graft rejection. Kidney Int 1989; 37: 602
27. Senitzer D, Greenstein SM, Louis P et al. Monitoring serum IL-2R levels in cadaver renal transplantation: a prospective, blinded study. Transplant Proc 1991; 23: 1279-1281
28. Meyer M, Paushter D, Steinmuller DR. The use of duplex Doppler ultrasonography to evaluate renal allograft dysfunction. Transplantation 1990; 50: 974-978
29. + graft infiltrating cells. Transplantation 1990; 50: 996-1000
30. Krieger NR, Yin DP, Garrison Fathman C. CD4+ but not CDS + cells are essential for allorejection. J Exp Med 1996; 184: 2013-2018
31. Yang J, Li X-W, Zheng F-L, Bi Z-Q. Evaluation of serum immunological parameters in acute renal allograft rejection. Transplant Proc 1996; 28: 1443-1444
32. Beik AI, Morris AG, Higgins RM, Lam FT. Serial flow cytometric analysis of T-cell surface markers can be useful in differential diagnosis of renal allograft dysfunction. Clin Transplant 1998; 12: 24-29
33. Oliveira JG, Ramos JP, Xavier P, Magalhaes MC, Mondes AA, Guerra LE. Analysis of fine-needle aspiration biopsies by flow cytometry in kidney transplant patients. Transplantation 1997; 64: 97-102
34. Rook AH, Quinnan GV, Frederick JR, Manischewitz JF, Kirmani N. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med 1984; 76: 385-392
35. Jacobs U, Klehr HU. Predictive value of immunological parameters in the early diagnosis of cytomegalovirus infection in renal transplantation. Transplant Proc 1993; 25: 2670
36. + T-cell subset in kidney transplant recipients. Transplantation 1998; 65: 279-282
37. Ninova DI, Wiesner RH, Gores GJ, Harrison JM, Krom RA, Homburger HA. Soluble T lymphocyte marker in the diagnosis of cellular rejection and cytomegalovirus hepatitis in liver transplant recipients. J Hepatol 1994; 21: 1080-1085
38. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135-141
39. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporinc ncphropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100
40. Colvin RB, Preffer FI, Fuller TC et al. A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Transplantation 1989; 48: 800-805
41. Keil M, Pec MK, Schenn G et al. Value of serum soluble tumour necrosis factor concentrations in the diagnosis and prognosis of renal graft rejection. Nephrol Dial Transplant 1994; 9: 815-819
42. Fujimoto J, Stewart SJ, Levy R. Immunochemical analysis of the released Leu-2 (T8) molecule. J Exp Med 1984; 160: 116-124
43. Bazil V, Strominger JL. Shedding as a mechanism for down-modulation of CD14 on stimulated human monocytes. J Immunol 1991; 147: 1567-1574
44. Giblin P, Ledbetter JA, Kavathas P. A secreted form of the human lymphocyte cell surface molecule CD8 arises from alternative splicing. Proc Natl Acad Sci USA 1989; 86: 998-1002
45. Norment AM, Lonberg N, Lacy E, Littman DR. Alternatively spliced mRNA encodes a secreted form of human CD8a. Characterization of the human CD8a gene. J Immunol 1989; 142: 3312-3319
46. Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL. Soluble CD8 during T cell activation. J Immunol 1989; 142: 2230-2236
47. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329
48. Goto H, Gidlund M. Soluble CD4. A link between specific immune mechanisms and non-specific inflammatory responses? Scand J Immunol 1996; 43: 690-692